3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
4
Gastrointestinal
2
Dermatologic
2
Gynecologic
1
Genitourinary
1
Endocrine
1
Breast
1
Conditions
Neuroendocrine Tumors
148
Carcinoma, Neuroendocrine
57
Thyroid Cancer, Papillary
54
Pheochromocytoma
52
Thyroid Neoplasms
42
Paraganglioma
42
Pituitary Neoplasms
40
Neoplasms
32
Adrenocortical Carcinoma
31
Multiple Endocrine Neoplasia Type 1
29
Gastro-enteropancreatic neuroendocrine tumor
29
Thyroid Carcinoma, Anaplastic
24
Lung Neoplasms
22
Small Cell Lung Carcinoma
21
Sarcoma
20
Carcinoid Tumor
20
Breast Neoplasms
19
Neoplasm Metastasis
18
Carcinoma, Non-Small-Cell Lung
18
Adenoma, Islet Cell
18
Melanoma
17
Carcinoma, Hepatocellular
17
Pancreatic Neoplasms
16
Colorectal Neoplasms
16
Adrenal Gland Neoplasms
16
Prostatic Neoplasms
15
Ovarian Neoplasms
15
Neuroblastoma
15
Carcinoma, Renal Cell
15
Adenocarcinoma, Follicular
15
Interventions
osimertinib
1
cemiplimab
1
Vascular Endothelial Growth Factor A
1
Paclitaxel
1
Docetaxel
1
Carboplatin
1
Antibodies, Bispecific
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lethal Congenital Contracture Syndrome 2
×
Endocrine
×
1 year
×
Clear all
NCT05142189
2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1
Recruiting
320 enrolled